Deep Health AI India Ltd Valuation Shifts Signal Price Attractiveness Challenges

Valuation Metrics: A Closer Look

Deep Health AI’s current price-to-earnings (P/E) ratio stands at 5.85, which, while appearing low in absolute terms, has been reclassified from fair to expensive relative to its historical valuation and peer group benchmarks. The price-to-book value (P/BV) ratio remains modest at 0.53, suggesting the stock is trading below its book value. However, the enterprise value to EBITDA (EV/EBITDA) multiple at 14.06 is elevated compared to several peers, indicating a higher valuation premium on operating earnings.

Other valuation indicators include an EV to capital employed ratio of 0.44 and an EV to sales multiple of 4.08. The PEG ratio, which adjusts the P/E for earnings growth, is exceptionally low at 0.08, signalling that the market may be pricing in minimal growth prospects or reflecting concerns about earnings sustainability.

Comparative Peer Analysis

When benchmarked against key competitors in the Gems, Jewellery and Watches industry, Deep Health AI’s valuation profile appears stretched. For instance, T B Z, rated as very attractive, trades at a P/E of 9.59 and an EV/EBITDA of 7.45, both indicating a more reasonable valuation given its fundamentals. Motisons Jewel, another attractive stock, commands a significantly higher P/E of 27.61 and EV/EBITDA of 20.66, reflecting stronger growth expectations and market confidence.

Other peers such as Shanti Gold and Radhika Jeweltec also maintain attractive valuations with P/E ratios around 10 and EV/EBITDA multiples below 8, underscoring Deep Health AI’s relatively expensive standing despite its micro-cap status.

Financial Performance and Returns

Deep Health AI’s return on capital employed (ROCE) is 7.83%, while return on equity (ROE) is 13.41%, figures that are modest but not alarming. The dividend yield of 5.26% offers some income cushion for investors, yet the company’s stock price has struggled, with a year-to-date return of -67.69% and a one-year decline of -57.96%, significantly underperforming the Sensex, which has gained 9.7% YTD and 3.57% over one year.

The stock’s 52-week high was ₹10.29, but it currently trades near its 52-week low of ₹1.65, closing at ₹1.90 on the latest session with a 2.15% day gain. This volatility and steep decline highlight the market’s scepticism about the company’s near-term prospects despite its valuation shift.

Mojo Score and Market Sentiment

Deep Health AI’s Mojo Score has deteriorated to 17.0, with the Mojo Grade downgraded from Sell to Strong Sell as of 12 Dec 2025. This downgrade reflects growing concerns over the company’s fundamentals, valuation, and market positioning. The micro-cap classification further emphasises the stock’s higher risk profile, with limited liquidity and greater susceptibility to market swings.

Despite the recent slight uptick in price, the overall sentiment remains cautious. The valuation grade change from fair to expensive suggests that investors may be overpaying relative to the company’s earnings and growth outlook, especially when compared to more attractively valued peers.

Sector Context and Broader Market Comparison

The Gems, Jewellery and Watches sector has faced headwinds from fluctuating consumer demand, input cost pressures, and global economic uncertainties. Within this context, Deep Health AI’s valuation shift is particularly notable given its underperformance relative to the broader market. The Sensex’s positive returns over one and three years contrast sharply with Deep Health AI’s steep losses, underscoring the stock’s challenges in delivering shareholder value.

Investors should weigh the company’s modest profitability metrics and dividend yield against its valuation premium and weak price momentum. The elevated EV/EBITDA multiple relative to peers signals that the market may be pricing in expectations of operational improvements or strategic initiatives that have yet to materialise.

Investor Takeaway

While Deep Health AI India Ltd’s valuation metrics have shifted towards expensive territory, the company’s fundamentals and price performance paint a more cautious picture. The low P/E ratio juxtaposed with an expensive valuation grade suggests that earnings quality or growth prospects may be under scrutiny. Investors should consider the company’s relative underperformance against the Sensex and peers, alongside its modest returns on capital and equity.

Given the downgrade to a Strong Sell rating and the micro-cap status, risk-averse investors might prefer to explore more attractively valued and fundamentally stronger alternatives within the sector or broader market. The company’s dividend yield offers some income appeal, but this may not compensate for the valuation premium and price volatility observed.

In summary, Deep Health AI’s valuation shift signals a need for careful analysis before committing capital, with a focus on monitoring operational improvements, sector dynamics, and comparative valuations to identify potential entry points or exit strategies.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →